Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...

Raptor Pharmaceutical to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference NOVATO, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will present at the following conference: Julie Anne Smith, President and Chief...

Raptor Pharmaceutical to Hold First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, May 7, 2015 at 4:30 p.m. EDT NOVATO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2015 financial results on Thursday, May 7, 2015...